{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:48:49Z","timestamp":1787590129440,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"DOI":"10.7759\/cureus.87903","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:26:17Z","timestamp":1752506777000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Efficacy of Upadacitinib in Patients With Ulcerative Colitis"],"prefix":"10.7759","author":[{"given":"Abdul","family":"Ghaffar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Collum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linta","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.034","article-title":"Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot","volume":"160","author":"Parigi TL","year":"2021","unstructured":"Parigi TL, D'Amico F, Danese S. Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot. Gastroenterology. 2021, 160:1472-4. 10.1053\/j.gastro.2020.04.034","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.013","article-title":"Entering the era of disease modification in inflammatory bowel disease","volume":"162","author":"Hart AL","year":"2022","unstructured":"Hart AL, Rubin DT. Entering the era of disease modification in inflammatory bowel disease. Gastroenterology. 2022, 162:1367-9. 10.1053\/j.gastro.2022.02.013","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier JM","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al.. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018, 2:23. 10.1186\/s41927-018-0031-x","journal-title":"BMC Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, et al.. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology. 2020, 158:2123-2138.e8. 10.1053\/j.gastro.2020.01.047","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al.. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020, 158:2139-49.e14. 10.1053\/j.gastro.2020.02.030","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen SB","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al.. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021, 80:304-11. 10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"ref7","article-title":"Drug Approval Package: RINVOQ. U.S. Food and Drug Administration Website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000TOC.cfm. Accessed February 25","year":"2019","unstructured":"Drug Approval Package. RINVOQ (Upadacitinib). United States Food and Drug Administration, Springfield, MD; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000Approv.pdf."},{"key":"ref8","unstructured":"NHS Health Resrach Authority. Consent in research. (2018). Accessed: May 29, 2025: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/policies-standards-legislation\/data-protection-and-information...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01364-0","article-title":"Systematic review with meta-analysis: efficacy and safety of upadacitinib in managing moderate-to-severe Crohn's disease and ulcerative colitis","volume":"44","author":"Niu C","year":"2024","unstructured":"Niu C, Zhang J, Napel M, et al.. Systematic review with meta-analysis: efficacy and safety of upadacitinib in managing moderate-to-severe Crohn's disease and ulcerative colitis. Clin Drug Investig. 2024, 44:371-85. 10.1007\/s40261-024-01364-0","journal-title":"Clin Drug Investig"},{"key":"ref10","article-title":"Upadacitinib for treating moderately to severely active ulcerative colitis","year":"2023","unstructured":"Upadacitinib for Treating Moderately to Severely Active Ulcerative Colitis . National Institute for Health and Care Excellence, London, UK; 2023. https.\/\/www.nice.org.uk\/guidance\/ta856\/resources\/upadacitinib-for-treating-moderately-to-severely-active-ulcerative-c...."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese MC","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, et al.. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016, 68:2857-66. 10.1002\/art.39808","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese S","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al.. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022, 399:2113-28. 10.1016\/S0140-6736(22)00581-5","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn's disease: prospective real-world experience","volume":"21","author":"Friedberg S","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, et al.. Upadacitinib is effective and safe in both ulcerative colitis and Crohn's disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023, 21:1913-23.e2. 10.1016\/j.cgh.2023.03.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab M","year":"2025","unstructured":"Shehab M, Alrashed F, Alsayegh A, et al.. Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2025, 23:250-62. 10.1016\/j.cgh.2024.07.033","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371204-real-world-efficacy-of-upadacitinib-in-patients-with-ulcerative-colitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:26:18Z","timestamp":1752506778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371204-real-world-efficacy-of-upadacitinib-in-patients-with-ulcerative-colitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.87903","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}